Future OncologyVol. 9, No. 5 EditorialImmunotherapy in lung cancer: the potential of cancer stem cells in future therapiesBrian J Morrison, Jason C Steel & John C MorrisBrian J MorrisonDivision of Hematology–Oncology, Department of Medicine, University of Cincinnati, Cincinnati, OH 45267-0562, USASearch for more papers by this author, Jason C SteelDivision of Hematology–Oncology, Department of Medicine, University of Cincinnati, Cincinnati, OH 45267-0562, USASearch for more papers by this author & John C Morris* Author for correspondenceDivision of Hematology–Oncology, Department of Medicine, University of Cincinnati, Cincinnati, OH 45267-0562, USA. .Search for more papers by this authorEmail the corresponding author at morri2j7@ucmail.uc.eduPublished Online:7 May 2013https://doi.org/10.2217/fon.13.38AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: cancer stem celldendritic cellgalectin-3immunotherapylung cancerReferences1 Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J. Clin.63(1),11–30 (2013).Crossref, Medline, Google Scholar2 Morrison BJ, Morris JC, Steel JC. Lung cancer-initiating cells: a novel target for cancer therapy. Target. Oncol. doi:10.1007/s11523-012-0247-4 (2013) (Epub ahead of print).Medline, Google Scholar3 Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat. Rev. Cancer12(2),133–143 (2012).Crossref, Medline, CAS, Google Scholar4 Eramo A, Lotti F, Sette G et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ.15(3),504–514 (2008).Crossref, Medline, CAS, Google Scholar5 Swann JB, Smyth MJ. Immune surveillance of tumors. J. Clin. Invest.117(5),1137–1146 (2007).Crossref, Medline, CAS, Google Scholar6 Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol.14,233–258 (1996).Crossref, Medline, CAS, Google Scholar7 Kaiser AD, Schuster K, Gadiot J et al. Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8(+) T cells. Eur. J. Immunol.42(3),662–671 (2012).Crossref, Medline, CAS, Google Scholar8 Morrison BJ, Steel JC, Morris JC. Sphere culture of murine lung cancer cell lines are enriched with cancer initiating cells. PLoS One7(11),e49752 (2012).Crossref, Medline, CAS, Google Scholar9 Li F, Tiede B, Massague J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res.17(1),3–14 (2007).Crossref, Medline, CAS, Google Scholar10 Morrison BJ, Schmidt CW, Lakhani SR, Reynolds BA, Lopez JA. Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res.10(4),210 (2008).Crossref, Medline, Google Scholar11 Smith LM, Nesterova A, Ryan MC et al. CD133/prominin-1 is a potential therapeutic target for antibody–drug conjugates in hepatocellular and gastric cancers. Br. J. Cancer99(1),100–109 (2008).Crossref, Medline, CAS, Google Scholar12 Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med.12(10),1167–1174 (2006).Crossref, Medline, Google Scholar13 Deonarain MP, Kousparou CA, Epenetos AA. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs1(1),12–25 (2009).Crossref, Medline, Google Scholar14 Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Part I: vaccines for solid tumours. Lancet Oncol.5(11),681–689 (2004).Crossref, Medline, CAS, Google Scholar15 Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature392(6673),245–252 (1998).Crossref, Medline, CAS, Google Scholar16 Xu Q, Liu G, Yuan X et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells27(8),1734–1740 (2009).Crossref, Medline, CAS, Google Scholar17 Yaddanapudi K, Mitchell RA, Putty K et al. Vaccination with embryonic stem cells protects against lung cancer: is a broad-spectrum prophylactic vaccine against cancer possible? PLoS One7(7),e42289 (2012).Crossref, Medline, CAS, Google Scholar18 Morrison BJ, Hastie ML, Grewal YS et al. Proteomic comparison of MCF-7 tumour sphere and monolayer cultures. PLoS One7(12),e52692 (2012).Crossref, Medline, CAS, Google Scholar19 Wang Y, Nangia-Makker P, Balan V, Hogan V, Raz A. Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. Cell Death Dis.1,e101 (2010).Crossref, Medline, CAS, Google Scholar20 Chauhan D, Li G, Podar K et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res.65(18),8350–8358 (2005).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByReduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells26 April 2018 | BMC Cancer, Vol. 18, No. 1SapC–DOPS Nanovesicles as Targeted Therapy for Lung Cancer9 February 2015 | Molecular Cancer Therapeutics, Vol. 14, No. 2 Vol. 9, No. 5 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 142 times History Published online 7 May 2013 Published in print May 2013 Information© Future Medicine LtdKeywordscancer stem celldendritic cellgalectin-3immunotherapylung cancerFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download